IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.

Rhea-AI Summary

Silo Pharma, a developmental stage biopharmaceutical company, announced its partnership with IBN to enhance corporate communications. This collaboration aims to leverage IBN's extensive investor distribution network to raise awareness for Silo's innovative therapeutic solutions targeting PTSD, Alzheimer’s, and other neurological disorders. Silo has established research agreements with leading universities, including studies on ketamine and psilocybin for Parkinson’s disease and inflammation. This partnership underscores Silo's commitment to advancing medical research and developing transformative treatments.

Positive

• Partnership with IBN to improve corporate communications and investor outreach.
• Established research agreements with multiple leading universities, enhancing credibility.
• Studies on psilocybin and ketamine may advance treatment options for neurological disorders.

Negative

• None.

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announces it has selected the corporate communications expertise of IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities.

Silo is committed to developing innovative solutions to address conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. The company works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization.

To date, Silo has entered into research agreements and partnerships with multiple leading medical universities, including:

• A sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease;
• A scientific research agreement with the University of California San Francisco (UCSF) leveraging four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation;
• An exclusive license agreement with the University of Maryland, Baltimore (UMB) to explore a patent focused on enhanced targeting of therapeutic agents to the central nervous system;
• A second exclusive option agreement with UMB to license a joint-homing peptide targeted at arthritis-inflamed joints; and
• An agreement with Columbia University granting it an option to license two distinct assets currently under development, one focused on Alzheimer’s disease and a second focused on PTSD and stress.
  
  

As part of the Client Partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Silo Pharma.

With 15+ years of experience assisting 500+ client partners improve communications within the investment community, and a sizable family of 50+ trusted brands, IBN has amassed a collective audience that includes millions of social media followers. IBN is uniquely positioned to provide Silo Pharma the solutions needed to reach a wide audience of investors, consumers, journalists and the general public.

“Through partnerships with world-class medical research partners, Silo is uniquely positioned to drive significant advances in the medical and psychedelic space,” states Chris Johnson, Director of Client Solutions for IBN. “We’re excited to customize our comprehensive suite of corporate communications solutions for the company as it works alongside its partners to develop innovative solutions that improve the lives of people impacted by a number of currently underserved conditions.”

To learn more about Silo Pharma, visit the company's corporate newsroom profile at www.ibn.fm/SILO

About Silo Pharma

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which the company believes will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com

About IBN

IBN (InvestorBrandNetwork) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

FAQ

What is the recent press release about Silo Pharma (SILO)?

Silo Pharma announced a partnership with IBN for corporate communications to enhance investor outreach and awareness of its therapeutic solutions.

What universities is Silo Pharma collaborating with for research?

Silo Pharma has entered agreements with Maastricht University, UCSF, and the University of Maryland, among others, for various research initiatives.

What disorders does Silo Pharma aim to address?

Silo Pharma focuses on conditions such as PTSD, Alzheimer’s disease, fibromyalgia, and Parkinson’s disease.

How does the partnership with IBN benefit Silo Pharma?

The partnership with IBN utilizes its investor distribution network to generate greater awareness and improve communications regarding Silo's research and innovations.

What innovative solutions is Silo Pharma developing?

Silo Pharma is developing therapeutic solutions combining traditional medicine with psychedelic research to treat various neurological disorders.